



































dOral Science International 9 (2012) 33– 37
Contents lists available at SciVerse ScienceDirect
Oral  Science  International
jo ur n al homepage: www.elsev ier .com/ locate /os i
riginal  Article
educed  expression  of  nuclear  factor  kB  in  oral  mucosa  undergoing
reoperative  chemoradiotherapy
etsuro  Ikebea,b,∗,  Keiko  Yamasakia, Yasuo  Takamunea, Hideki  Nakayamaa,  Masanori  Shinoharaa
Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjyo, Kumamoto 860-8556, Japan
Department of Oral and Maxillofacial Surgery, Fukuoka Dental College, 2-15-1 Tamura, Sawara-ku, Fukuoka 814-0193, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 29 September 2011
eceived in revised form 18 January 2012
ccepted 26 January 2012
eywords:
ral mucosa
a  b  s  t  r  a  c  t
Radiotherapy  as well  as chemotherapy  in  head  and  neck  cancer  induces  severe  oral  mucositis.  Even
after  healing  of the  mucositis,  however,  the  oral  mucosa  looking  atrophic  is  known  to  be  susceptible
to  injury  and  infection.  In order  to investigate  such  vulnerability  of  mucosa,  we  immunohistochemi-
cally  studied  the expressions  of  Ki-67,  proliferating  cell  nuclear  antigen  (PCNA),  cyclin  D1, nuclear  factor
(NF)-kB,  and  keratinocyte  growth  factor  (KGF)  receptor  in  the  oral  mucosal  keratinocytes  undergoing




without  such  therapy.  As  a result,  the  expressions  of  Ki-67,  PCNA,  and  cyclin  D1 were decreased  in  the
chemoradiotherapy-treated  oral keratinocytes.  Interestingly,  NF-kB  expression,  which  is  known  to be
enhanced  in  oral  mucositis,  was  reduced  after  chemoradiotherapy.  The  chemoradiotherapy  had  no effect
on  the  expression  of KGF  receptor  in  oral  keratinocytes.  In  conclusion,  the  vulnerability  of oral  mucosa




Radiotherapy, as well as chemotherapy, on head and neck cancer
nduces severe oral mucositis [1]. This radiation-induced or anti-
ancer drug-induced oral mucositis spontaneously heals 3–4 weeks
fter treatment. In particular, the oral mucosa once exposed to radi-
tion appears to become atrophic and susceptible to injury even
fter the complete reepithelialization of mucosa. We  often experi-
nce that the mechanical stress such as an irritation by food and
mproper denture on such radiated mucosa easily induces ulcera-
ion even if the oral mucosa appears to be healthy. If such ulceration
ccurs on gingiva, it may  cause infection of alveolar bones and trig-
er the occurrence of osteoradionecrosis of the jaw. Hence, oral
are for patients with head and neck cancer after radiotherapy or
hemoradiotherapy is crucial. However, the reason why  the oral
ucosa exposed to radiation is atrophic and vulnerable remains
nknown.
In order to understand the biological properties of oral mucosa
ndergoing radiotherapy or chemotherapy, the accumulating
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knowledge about the mechanisms of radiation- or chemotherapy-
induced oral mucositis may  be helpful.
Oral mucositis is an adverse effect arising in almost all patients
with head and neck cancer undergoing radiotherapy or chemother-
apy, which impairs the food intake because of severe oral pain
and bleeding, and worsens the quality of life of the patients [2].
It is a great beneﬁt to the patients if radiation- or anticancer drug-
induced oral mucositis is well relieved [3,4]. The management for
oral mucositis should be based on the pathobiology for radiation-
or anticancer drug-induced oral mucositis.
In radiotherapy, the onset of oral mucositis is a biologically com-
plex process [5]. It is thought that radiation damages two  types
of cells in oral mucosa, squamous epithelial cells (keratinocytes)
and submucosal stromal cells (ﬁbroblasts and vascular endothelial
cells). Radiation and radiation-generated reactive oxygen species
(ROS) damage DNA itself, inhibit cell proliferation, and trigger the
apoptosis or necrosis of oral keratinocytes, which gives rise to the
breakdown of squamous cell layer to result in ulceration [5]. In
addition, the arrest of cell cycle suppresses the mucosal regener-
ation and the wound healing process. As a result, refractory oral
mucositis develops.
In  the initiation stage of radiation-induced mucositis, DNA dam-
age and ROS trigger the activation of transcription factors such as
nuclear factor-kB (NF-kB), AP-1, and p53 [5–7]. Among them, NF-
kB seems to be a key transcription factor in the establishment of
mucositis [8]. NF-kB activation can upregulate the expression of
evier Ltd. All rights reserved.
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Table 1
Patients characteristics.
Group S (n = 10)a Group Ra (n = 10)
Male:female 3:7 8:2
Age  (years) 63.5  (50–82) 57.2 (49–72)
Tumor  location
Tongue 4 1
Lower  gum 3  3
Oral  ﬂoor 2 4
Buccal  mucosa 1
Upper  gum 0 1
Histopathological responseb
Grade IIa – 2
Grade  IIb –  2
Grade  III – 1
Grade  IV – 5
a Group S, the cases without radiotherapy; Group Ra, the cases with chemoradio-
therapy.
b Histopathological response assessment. Grade IIa, obliteration of tumor struc-
tures  was  mild and viable tumor cells were observed in more than 25%; Grade IIb,
obliteration of tumor structures was severe and viable tumor cells were observed in





































D1. In this context, the expression of NF-kB was studied immuno-
histochemically using anti-p65 subunit of NF-kB antibodies (Fig. 2).ro-inﬂammatory cytokines including tumor necrosis factor (TNF)
, interleukin (IL)-1, and IL-6 [8]. It seems likely that the increased
evels of these cytokines induce inﬂammatory reactions in oral
ucosa, promote the damage of the underlying connective tissues,
educe epithelial oxygenation, and ultimately result in epithelial
asal cell death and injury. Since TNF and IL-1 are efﬁcient acti-
ators of NF-kB, the repeated NF-kB activation by them may  amplify
he mucosal damage in a vicious circle [5].
If NF-kB plays a central role in the development of radiation-
nduced mucositis, it may  be also implicated in the vulnerability
f normal oral mucosa undergoing chemoradiotherapy. However,
here have been few reports studying the expression of NF-kB in
uman oral mucosa after chemoradiotherapy. Usually we have no
ccasions to take specimens from normal oral mucosa after the
ealing of oral mucositis. In the present study, instead, we observed
he expression of NF-kB in the non-cancerous oral mucosa which
as present in the specimens dissected from oral cancer patients
ndergoing preoperative concurrent chemoradiotherapy, compar-
ng with those from the patients without chemoradiotherapy.
. Materials and methods
.1.  Subjects
Twenty consecutive patients with primary oral squamous cell
arcinoma (OSCC), who presented to the Department of Oral
nd Maxillofacial Surgery, Graduate School of Medical Sciences,
umamoto University Hospital from January 2003 to July 2003,
ollowed with tumor surgery, were divided into two  groups. One
roup (n = 10) consists of the patients who underwent preoperative
oncurrent chemoradiotherapy, that is radiotherapy (total 30 Gy;
 Gy per a day for 15 days) combined with oral administration of
-1 for 14 days, prior to surgery (Group Ra), and the other (n = 10)
s the group of the patients who were operated on without preop-
rative chemoradiotherapy (Group S). The clinical details of both
roups are shown in Table 1. In all the patients of Group Ra, oral
ucositis occurred, which was treated with lidocaine-containing
ral rinse and corticosteroid powder. Three to four weeks after
he end of chemoradiotherapy, when oral mucositis was almost
eepithelialized and healed, tumor surgery was performed.national 9 (2012) 33– 37
2.2. Immunohistochemical staining
Four-micrometer-thick histological sections of 4%
paraformaldehyde ﬁxed, parafﬁn embedded tissues were formed
from the tumor specimens, mounted, and air-dried. The sections
were deparafﬁnized in xylene and rehydrated in ethanol, and
endogenous peroxidase was blocked by immersion in methanol
containing 0.3% hydrogen peroxidase for 30 min. The sections
were incubated overnight at 4 ◦C with their respective pri-
mary antibodies, then for 30 min  at room temperature with the
peroxidase-conjugated anti-mouse or anti-rabbit IgG Ab, fol-
lowed by staining with diaminobenzidine (Histoﬁne MAX-PO kit,
Nichirei, Tokyo, Japan) [9]. The primary antibodies used were as
follows: mouse anti-cyclin D1 monoclonal antibody (Invitrogen,
Life Technologies Japan Ltd., Osaka, Japan), mouse anti-Ki67
monoclonal antibody (Invitrogen, Life Technologies Japan Ltd.),
rabbit anti-keratinocyte growth factor (KGF) receptor polyclonal
antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
rabbit anti-NF-B p65 polyclonal antibodies (Santa Cruz Biotech-
nology, Inc.), mouse anti-PCNA monoclonal antibody (Santa Cruz
Biotechnology, Inc.).
Two  independent researchers (K.Y. and Y.T.) determined the
microscopic views on the areas located away from tumor nests,
where only the normal keratinocytes were observed without any
cancerous cells and atypical cells and which appeared to be best
stained, and they counted the number of all the cells and the pos-
itively stained cells in the squamous cell layer, respectively. The
rates of the positively stained cells were calculated as the positive
cell numbers per total cell numbers. The average rates from two
researchers were regarded as the results. Statistical signiﬁcance of
the rates of the positively stained cells between Group S and Group
Ra was assessed with paired one-way ANOVA, where appropriate
p-value of <0.05 was considered to be signiﬁcant.
3. Results
We  took the non-cancerous oral mucosa specimens from the
extirpated oral cancer tissues, which were located away from tumor
nests and consisted of normal keratinocytes. Oral mucosa in Group
Ra had been exposed to total 30 Gy of radiation concurrently cou-
pled with S-1 administration 3–4 weeks before, while the tumors in
Group S were treated surgically without chemoradiotherapy. The
difference between both groups is whether the given oral mucosa
underwent chemoradiotherapy or not.
In order to study the effects of chemoradiotherapy on oral
mucosa, at ﬁrst, we  immunohistochemically investigated the
expression of several cell growth markers such as Ki-67, PCNA, and
cyclin D1 in the oral keratinocytes from both groups (Fig. 1). The
rates of the positive cells expressing Ki-67 were 6.0% in Group S
and 1.1% in Group Ra. For the expression of PCNA, the rates of the
positive cells in Group S and Group Ra were 26.8% and 9.4%, respec-
tively. Like Ki67 and PCNA, 8.9% of the keratinocytes in Group S and
2.7% of those in Group Ra expressed cyclin D1 (Fig. 1). Statistically,
there was a signiﬁcant difference in the expression of each growth
marker between both groups (p < 0.05). The growth activity of irra-
diated keratinocytes in oral mucosa seemed to be reduced after the
mucositis previously arising in the same area was  healed.
Sonis  has reported that a transcription factor NF-kB plays a
critical role in the occurrence of radiation-induced oral mucositis
[5]. NF-kB activates not only the expression of pro-inﬂammatory
cytokines, leading to mucositis, but also the expression of cyclinThe keratinocytes in Group S contained 8.5% of the NF-kB-positive
cells, which were mainly located in basal cell layer, while Group Ra
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Fig. 1. Growth activities of the oral mucosa undergoing radiation. The non-cancerous oral mucosal specimens were taken from the patients who underwent the tumor
surgery only without radiation (Group S) (A, C, E) and from the patients who  had undergone the preoperative radiotherapy against oral cancer 3–4 weeks before (Group Ra)
(B,  D, F). The specimens were immunostained with anti-Ki-67 (A, B), anti-proliferating cell nuclear antigen (PCNA) (C, D), or anti-cyclin D1 antibodies (E, F).
Fig. 2. Nuclear factor (NF)-kB expression in the oral mucosa undergoing radiation. NF-kB expression was examined immunohistochemically using anti-p65 subunit of NF-kB
antibodies in the non-radiated, healthy-looking oral mucosa (Group S) (A), the radiated non-cancerous oral mucosa (Group Ra) (B), and oral squamous cell carcinoma (SCC)
without radiotherapy (Group S) (C).
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Fig. 3. The expression of keratinocyte growth factor receptor (KGF-R) in the oral mucosa undergoing radiation. The expression of KGF-R was examined immunohistochemically
using anti-KGF-R antibodies in the non-radiated, non-cancerous oral mucosa in the resected oral cancer specimens (Group S) and in the non-cancerous oral mucosa in the






































mad few NF-kB-positive cells at the rate of 1.4% (Fig. 2). There was
 signiﬁcant difference for NF-kB expression between both groups
p < 0.05). On the other hand, OSCCs expressed much higher levels
f NF-kB than non-cancerous keratinocytes (Fig. 2). It is assumed
hat NF-kB, which was once activated in radiation-induced oral
ucositis, is rather suppressed to lower levels than normal.
Recently, radiation or chemotherapy-induced mucositis has
een reported to be treated with KGF1, which stimulates the prolif-
ration of keratinocytes to promote the regeneration of epithelium.
hen the expression of KGF receptors was examined in oral
ucosa, the positive cells expressing KGF receptors in Group S and
roup Ra were 7.6% and 6.3%, respectively, which shows no signif-
cant difference (Fig. 3). KGF receptors were located in the spinar
ell layer as well as basal cell layer in Group S, but their location
eemed to be restricted to basal cell layer in Group Ra (Fig. 3) to
hich exogenously applied KGF may  be effective.
. Discussion
In our department, patients with the late stage of oral cancer
ave been treated with preoperative chemoradiotherapy consist-
ng of 30 Gy radiation and S-1, followed by surgery. Because the
ain treatment strategy for oral cancer is surgical extirpation
n our regimen, preoperative chemoradiotherapy is expected to
educe the tumor size. In cooperation with radiotherapists, 30 Gy
as determined to be enough for this purpose since S-1 is known
o enhance the sensitivity of cells to radiation. This regimen has
orked well [10], but the patients have suffered from severe oral
ucositis even at a 30 Gy dose. Hence, the biological effect of
hemoradiation on oral mucosa should be explored.
Irradiation on oral cancer gives rise to various adverse effects
n the tissues of oral cavity including mucosa, jaw bone, salivary
land, taste bud, dentition, and periodontium [11]. Oral mucositis
s an acute and transient adverse effect, while osteoradionecrosis of
he jaw is a formidable late effect associated with radiotherapy. Dry
outh and loss of taste also occur during radiotherapy and persist
ccasionally for a long time afterward [11]. In addition, it is known
hat the irradiated oral mucosa, even after the complete healing
f mucositis, becomes atrophic and susceptible to injury. Although
e are responsible for the management of the oral mucosa after
adiotherapy, there is little information about the molecular basis
or such vulnerability of radiated oral mucosa.
In order to understand the effect of chemoradiation on oral
ucosa, we immunohistochemically observed the oral mucosa,which  looked like normal epithelium, in the resected OSCC spec-
imens undergoing preoperative radiotherapy. As a result, the
growth activities of oral epithelium such as the expression of Ki-
67, PCNA, and cyclin D1 in keratinocytes seemed to be reduced
after radiation. Tobita et al. reported that radiation inhibits
the expression of Ki-67 dose-dependently in serum-free three-
dimensional cultures of human oral keratinocytes [12], whereas
Bonan et al. found the number of Ki-67-positive cells was  higher
in the tissues of radiation-induced oral mucositis than that in
normal mucosa [13]. Both studies investigated the expression
of Ki-67 in keratinocytes during radiation, but not after radia-
tion, when the mucositis healed. The reduced growth activity,
which we observed in the mucosa after radiation, may  be related
to the impaired regeneration and delayed wound healing of
mucosa, to which the vulnerability of radiated oral mucosa may
attribute.
We assumed that NF-kB is associated with the altered growth
activity and vulnerability of irradiated oral mucosa. In oral mucosi-
tis, radiation enhances the expression of NF-kB [5,6], which in turn
stimulates the production of the pro-inﬂammatory cytokines and
initiates mucositis [5]. Contrary to mucositis, the expression of
NF-kB in the basal keratinocytes was  reduced in the normal oral
mucosa after radiation, while non-radiated oral mucosa expressed
signiﬁcant levels of NF-kB and OSCCs expressed much higher levels
of NF-kB [9] as shown in Fig. 2. The reduced expression of NF-kB
is thought to be compatible with the reduced growth activity since
NF-kB is a transcription factor for cyclin D1 and involved in cell
growth [5,8]. Moreover, the reduction in NF-kB expression may
lead to the immunocompromised condition of mucosa because
such reduction in NF-kB may cause the decreased production of
the immunostimulators IL-1, IL-6, IL-8, and TNF. As NF-kB is also
involved in anti-apoptosis through Bcl-2 expression, the inhib-
ited NF-kB may  contribute to the apoptosis of oral keratinocytes
[5,8]. Thus, the fragility of the radiated oral mucosa may be due
to the inhibition of NF-kB. However, it remains unknown why  NF-
kB expression, once increased during radiotherapy, decreased after
radiotherapy.
It is critical to manage the oral mucosa undergoing radiotherapy.
There are various therapies to be applied to radiation-induced oral
mucositis [3,4]. Recently, palifermin (KGF1), which is also known
as ﬁbroblast growth factor 7 (FGF-7), has been reported to reduce
the severity and duration of radiotherapy- or chemotherapy-
induced oral mucositis [14,15]. KGF1 accelerates the proliferation
















[14]  Spielberger R, Stiff P, Bensinger W,  et al. Palifermin for oral mucositis afterT. Ikebe et al. / Oral Scienc
ucositis, palifermin may  also contribute to the care of fragile oral
ucosa with radiotherapy history because the receptor to KGF was
xpressed in not only the non-radiated oral mucosa, but also in the
adiated mucosa (Fig. 3).
In conclusion, chemoradiation exposure may  impair the regen-
ration ability of oral mucosa, even after the complete healing of
adiation-induced mucositis, through the reduced expression of
F-kB, which may  be involved in the vulnerability of oral mucosa.
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